Skip to main content
Premium Trial:

Request an Annual Quote

People In The News : Nov 5, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – RainDance Technologies has appointed Richard Lussier to be VP of worldwide sales and Ingrid Choupin to serve as managing director of European sales and marketing. Lussier previously was VP of worldwide sales and service at Cell Biosciences, and he worked in sales at Solexa, Fluidigm, and at Applera and Celera Genomics. Choupin formerly was associate director of global sales strategy at Affymetrix, and she worked in sales at Invitrogen.

Molecular Response has appointed Thomas Broudy to be its chief scientific officer and Richard Scuderi to be the firm's medical director. Broudy formerly was a director at AltheaDx, and Scuderi currently is a member of Pacific Rim Pathology.

Kathy Hudson, chief of staff for National Institutes of Health Director Francis Collins, has been appointed to the newly-created position of NIH Deputy Director for Science, Outreach, and Policy.

Hudson founded and directed the Genetics and Public Policy Center and was an associate professor at The Johns Hopkins University, which she left to take the post as Collins' chief of staff. She also formerly was assistant director of the National Human Genome Research Institute.

GATC subsidiary LifeCodexx has named Martin Burow to serve as head of the firm's commercial operations, where he will support prenatal diagnostics business efforts in European markets. Burow formerly was a senior manager in Brahms AG's Asia-Pacific business.

Genstruct has appointed Arnold Levine to a position on its board of directors, where he will help guide the company's scientific strategy and direction. Levine currently is a professor in the School of Natural Sciences at the Institute for Advanced Study, where he also leads the Simons Center for Systems Biology. He is recognized for his work in establishing p53 as a tumor suppressor protein.

Metamark Genetics has appointed Mark Straley to be president, CEO, and a member of the board of directors. Straley formerly was worldwide president of Johnson & Johnson's diagnostics division, and he worked at Bayer Healthcare and Abbot Laboratories. Metamark co-founder Kenneth Weg, who has been serving as interim-CEO, will continue to serve as chairman of the board of directors.

Med BioGene said this week that t has reduced its board of directors from eight members to four. The directors continuing with the firm are Erinn Broshko, who also is the firm's CEO, Heiner Dreismann, Dennis Grimaud, and Kevin Rooney. The others, Bruce Cousins, Hector MacKay-Dunn, Michael Hayden, and John Rayson, have resigned as directors.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.